<DOC>
	<DOCNO>NCT02698553</DOCNO>
	<brief_summary>Bupropion use psychological disorder mainly major depressive disorder ( MDD ) . In China , buproprion Immediate Release ( IR ) Sustained Release ( SR ) tablet market treatment MDD . Bupropion Hydrochloride ( HCl ) Extended Release ( XL ) tablets formulation propose marketing approval China indication . Therefore , pharmacokinetic study plan conduct Chinese subject . It open label , single-centre single cycle study evaluate pharmacokinetics , safety tolerability 150 milligram ( mg ) 300 mg follow single repeat daily dos . Approximately 16 male female Chinese healthy subject enrol study get 12 complete subject .</brief_summary>
	<brief_title>A Study Evaluate Pharmacokinetics , Safety Tolerability Extended-release Bupropion Hydrochloride Tablets Chinese Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Bupropion</mesh_term>
	<criteria>Able actively communicate investigator complete studyrelated document ; able understand content Informed consent form ( ICF ) sign write ICF prior studyspecific procedure . Males female age 18 45 year inclusive , time signing informed consent . Nonsmoking healthy male female assess medical history physical examination . Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter specifically list inclusion exclusion criterion , outside reference range population study may include Investigator agree document find unlikely introduce additional risk factor interfere study procedure . Body weight &gt; =50 kilogram ( Kg ) Body mass index ( BMI ) 19.0 25.0 kg/square meter ( m^2 ) . A female subject eligible participate : Childbearing potential negative pregnancy test determine serum urine human chorionic gonadotropin ( hCG ) test screen prior dose agrees use contraception method study follow contact . Male subject female partner childbearing potential must agree use contraception method study follow contact . ALT , ALP total bilirubin = &lt; 1.5x upper limit normal ( ULN ) ( isolated bilirubin &gt; 1.5x ULN acceptable bilirubin fractionate direct bilirubin &lt; 35 percent [ % ] ) . Based single average correct QT interval ( QTc ) value triplicate ECGs obtain brief recording period : QTc &lt; 450 millisecond ( msec ) QTc &lt; 480 msec subject bundle branch block . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . Drug alcohol abuse dependency within one year prior enrolment . History regular alcohol consumption within 6 month study , define : average weekly intake &gt; 14 drink . One drink equivalent 12 gram ( g ) alcohol : 12 ounce ( 360 millilitre [ ml ] ) beer , 5 ounce ( 150 ml ) wine 1.5 ounce ( 45 ml ) 80 proof distil spirit . Unstable disease condition ; laboratory measurement assess investigator clinically relevant ( include electroencephalogram [ EEG ] , ECG , haematology , biochemistry urine analysis , etc . ) ; disorder might interfere absorption , distribution , metabolism excretion study drug ; investigator 's opinion disease may lead safety concern interfere pharmacokinetics assessment . Subjects concurrent previous neuropsychological disorder , assess Columbia Suicidality Severity Rating ( CSSR ) Scale investigator , suicidal tendency , commit suicidal behavior/attempt . Known history cerebral trauma , previous cerebral disorder , seizure eat disorder , condition investigator 's opinion may increase risk seizure . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month Other Criteria Serum human immunodeficiency virus ( HIV ) antibody Syphilis antibody positive . A positive prestudy drug/alcohol screen . Blood donation 3 month prior enrolment . Where participation study would result donation blood blood product excess 500 ml within 56 day period . Obvious evidence active haematological disease , significant blood loss last 3 month . History sensitivity heparin heparininduced thrombocytopenia . The subject participate clinical trial receive investigational product within 30 day prior first dose day current study . Exposure four new chemical entity within 12 month prior first dose day . Known allergy Bupropion ExtendedRelease Tablets component . Lactating female woman child bear potential use oral implanted contraceptive within 30 day prior enrolment , receive injection chronically act contraceptive 1 year prior study initiation . Unable refrain use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication . Other condition , Investigator 's judgment , render subject unsuitable clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Major depressive disorder</keyword>
	<keyword>Extended release Bupropion</keyword>
</DOC>